Mikael Dolsten, the longtime Pfizer executive who led the company’s research and development operations, has withdrawn his candidacy for a seat on Novo Nordisk’s board. Novo Nordisk confirmed on Thursday that Dolsten informed the company he would not stand for election at its extraordinary general meeting, citing personal reasons for his decision. His withdrawal comes despite a career spanning senior R&D leadership roles at major pharmaceutical companies including Boehringer Ingelheim and AstraZeneca.
Novo Nordisk noted that the remaining board candidates listed in its Oct. 21 meeting notice will stand for election as planned, with no other changes announced. Dolsten’s exit adds another layer of complexity to an already turbulent period for the Danish drugmaker.
The company has recently undergone a significant governance shake-up driven by its largest shareholder, the Novo Nordisk Foundation. In October, the foundation initiated moves to take tighter control of the board, expressing a clear intention to focus more sharply on strengthening Novo Nordisk’s presence in the critical U.S. pharmaceutical market. This strategic shift aims to reignite momentum for Wegovy, the company’s blockbuster weight-loss drug, which has seen fluctuating sales performance.
The board restructuring triggered considerable upheaval, including the resignation of Novo’s chair and six independent board members. This unprecedented shift has also sparked frustration among minority shareholders. Many are preparing a protest vote against what they view as an aggressive overhaul imposed by the dominant shareholder, raising concerns about governance transparency and the balance of power within the organization.
Dolsten’s withdrawal arrives at a sensitive moment, as Novo Nordisk navigates shareholder tensions, recalibrates its leadership structure, and works to reinforce its market position amid booming global demand for obesity treatments.
